{
    "keywords" : [
            "diabetes",
            "diabetes mellitus",
            "zucker",
            "typ-2",
            "typ 2",
            "typ-2-diabetes"
    ],
    "active" : "true",
    "publisher" : "Programm für Nationale Versorgung",
    "diagnosis" : "Typ-2-Diabetes",
    "nameOfGuideline" : "Therapie des Typ-2-Diabetes",
    "source" : "http://evid.one/guideline-repository/nvl-001gk_S3_Typ-2-Diabetes_Therapie_2014-11-abgelaufen.pdf",
    "validity" : "2018-08-01",
    "internalAuthor" : "Johann Rink",
    "levels" : [
        {
            "levels" : [
                
            ],
            "recommendations": [
                {
                    "type": "group",
                    "title": "Basistherapie (Schulung, Ernährungstherapie, körperliche Aktivität, Raucher-Entwöhnung, Behandlung weiterer Risikofaktoren)",
                    "primaryRecommendation": true,
                    "recommendations": 
                    [
                        {
                            "type": "freeText",
                            "title": "",
                            "content": "Strukturiertes, evaluiertes Zielgruppen und Themenspezifisches Schulungs- und Behandlungszentrum",
                            "gradeOfEvidence": "",
                            "gradeOfRecommendation": "A",
                            "primaryRecommendation": true,
                            "comment": "<b>0</b>: Rezidivierende Schulungsangebote",
                            "hideOnSublevelSelect": false
                        },
                        {
                            "type": "freeText",
                            "title": "",
                            "content": "Ernährungsempfehlungen (gesunde, ausgewogene Kostform, keine Diabetesnahrung)",
                            "gradeOfEvidence": "",
                            "gradeOfRecommendation": "A",
                            "primaryRecommendation": true,
                            "comment": "",
                            "hideOnSublevelSelect": false,
                            "sourceRef": "page=34"
                        },
                        {
                            "type": "freeText",
                            "title": "",
                            "content": "Ernährungsberatung: Individuelle Ernährungsberatung anbieten",
                            "gradeOfEvidence": "",
                            "gradeOfRecommendation": "A",
                            "primaryRecommendation": true,
                            "comment": "",
                            "hideOnSublevelSelect": false
                        },
                        {
                            "type": "freeText",
                            "title": "",
                            "content": "Ausarbeitung eines individuellen Selbstmanagementplans",
                            "gradeOfEvidence": "",
                            "gradeOfRecommendation": "B",
                            "primaryRecommendation": true,
                            "comment": "",
                            "hideOnSublevelSelect": false
                        },
                        {
                            "type": "freeText",
                            "title": "",
                            "content": "Körperliche Aktivität: Individuelle Zielfestlegung",
                            "gradeOfEvidence": "",
                            "gradeOfRecommendation": "B",
                            "primaryRecommendation": true,
                            "comment": "<ul><li><b>B</b> Aufklärung</li><li><b>A</b> Teilnahme Strukturierte Bewegungsprogramme, individuelle Entscheidung</li><li><b>B</b> Training</li></ul>",
                            "hideOnSublevelSelect": false
                        },
                        {
                            "type": "freeText",
                            "title": "",
                            "content": "Tabakentwöhnung",
                            "gradeOfEvidence": "",
                            "gradeOfRecommendation": "A",
                            "primaryRecommendation": true,
                            "comment": "<ul><li><b>A</b> Aufklärung</li><li><b>A</b> Regelmäßige Beratung</li></ul>",
                            "hideOnSublevelSelect": false,
                            "sourceRef": "page=39"
                        }
                    ]
                },
                {
                    "type": "freeText",
                    "title": "",
                    "content": "Kein Erfolg zu erwarten: Direkt Stufe 2",
                    "gradeOfEvidence": "",
                    "gradeOfRecommendation": "0",
                    "primaryRecommendation": true,
                    "comment": "",
                    "hideOnSublevelSelect": false
                },
                {
                    "type": "freeText",
                    "title": "",
                    "content": "Minimale Wirkstoffdosis erfolgreich: Auslassversuch unter HbA1C Kontrolle",
                    "gradeOfEvidence": "",
                    "gradeOfRecommendation": "B",
                    "primaryRecommendation": true,
                    "comment": "",
                    "hideOnSublevelSelect": false
                },
                {
                    "type": "freeText",
                    "title": "",
                    "content": "Indikation für Plasmaglukose-Selbstmessung prüfen (Link S. 33)",
                    "gradeOfEvidence": "",
                    "gradeOfRecommendation": "B",
                    "primaryRecommendation": true,
                    "comment": "",
                    "hideOnSublevelSelect": false,
                    "sourceRef": "page=39"
                }
            ],
            "levelName" : "Stufe 1: Diagnostizierter Typ-2-Diabetes Mellitus",
            "levelId" : "06781160-b732-11e8-8097-87b5bf74cf76",
            "definition": "Diagnosekriterien über klinische Untersuchung oder über Algorithmus zur Diagnose eines Typ-2-Diabetes (Link S.27)"
        },
        {
            "levels": [
                {
                    "levelName" : "Metformin Unverträglichkeit / Kontraindikationen?",
                    "levelId" : "06781160-b732-11e8-8097-87b5bf74cf76",
                    "definition": "",
                    "recommendations": [
                        {
                            "type": "freeText",
                            "title": "Empfohlen von DEGAM/AkdÄ",
                            "primaryRecommendation": true,
                            "hideOnSublevelSelect": true,
                            "content": "Basistherapie mit Humaninsulin",
                            "gradeOfEvidence" : "",
                            "comment": "(positiver Nutzennachweiß)",
                            "gradeOfRecommendation" : ""
                        },
                        {
                            "type": "syntax",
                            "title": "Empfohlen von DEGAM/AkdÄ",
                            "primaryRecommendation": true,
                            "hideOnSublevelSelect": true,
                            "gradeOfEvidence" : "",
                            "gradeOfRecommendation" : "",
                            "content": "Basistherapie mit {0}",
                            "comment": "(positiver Nutzennachweiß)",
                            "preDefs": 
                            [
                                {
                                    "type": "medication",
                                    "name" : "Glibenclamid (Sulfonylharnstoff)",
                                    "refId": 0,
                                    "comment" : "(positiver Nutzennachweiß)",
                                    "activeSubstance" : "",
                                    "dosageAmount" : "0",
                                    "dosageUnit" : "ml",
                                    "useSpecificDosageSchema": true,
                                    "morningDosage" : "0",
                                    "noonDosage" : "0",
                                    "eveningDosage" : "0",
                                    "nightDosage" : "0",
                                    "dosageFrequency" : "0",
                                    "dosageDuration" : "0",
                                    "dosageDurationUnit" : "days",
                                    "unlimitedApplicationDuration": true
                                }
                            ]
                        },
                        {
                            "type": "syntax",
                            "title": "Empfohlen von DEGAM/AkdÄ",
                            "primaryRecommendation": false,
                            "hideOnSublevelSelect": true,
                            "content": "Basistherapie mit DPP-4-Inhibitor",
                            "gradeOfEvidence" : "",
                            "gradeOfRecommendation" : "",
                            "comment": "(Kein Nutzennachweiß)"
                        },
                        {
                            "type": "syntax",
                            "title": "Empfohlen von DEGAM/AkdÄ",
                            "primaryRecommendation": false,
                            "hideOnSublevelSelect": true,
                            "gradeOfEvidence" : "",
                            "gradeOfRecommendation" : "",
                            "content": "Basistherapie mit weitere Sulfonylharnstoffe / Glinid"
                        },
                        {
                            "type": "syntax",
                            "title": "Empfohlen von DDG/DGIM",
                            "primaryRecommendation": true,
                            "hideOnSublevelSelect": true,
                            "content": "Basistherapie mit DPP-4-Inhibitor",
                            "gradeOfEvidence" : "",
                            "gradeOfRecommendation" : ""
                        },
                        {
                            "type": "syntax",
                            "title": "Empfohlen von DDG/DGIM",
                            "primaryRecommendation": true,
                            "hideOnSublevelSelect": true,
                            "gradeOfEvidence" : "",
                            "gradeOfRecommendation" : "",
                            "content": "Basistherapie mit Insulin (häufig Verzögerungsinsuline)"
                        },
                        {
                            "type": "syntax",
                            "title": "Empfohlen von DDG/DGIM",
                            "primaryRecommendation": true,
                            "hideOnSublevelSelect": true,
                            "content": "Basistherapie mit SGLT-2-Inhibitor",
                            "gradeOfEvidence" : "",
                            "gradeOfRecommendation" : ""
                        },
                        {
                            "type": "syntax",
                            "title": "Empfohlen von DDG/DGIM",
                            "primaryRecommendation": true,
                            "hideOnSublevelSelect": true,
                            "gradeOfEvidence" : "",
                            "gradeOfRecommendation" : "",
                            "content": "Basistherapie mit Sulfonylharnstoff / Glinid"
                        },
                        {
                            "type": "syntax",
                            "title": "Empfohlen von DDG/DGIM",
                            "primaryRecommendation": false,
                            "hideOnSublevelSelect": true,
                            "gradeOfEvidence" : "",
                            "gradeOfRecommendation" : "",
                            "content": "Basistherapie mit Glukosidasehemmer"
                        },
                        {
                            "type": "syntax",
                            "title": "Empfohlen von DDG/DGIM",
                            "primaryRecommendation": false,
                            "hideOnSublevelSelect": true,
                            "gradeOfEvidence" : "",
                            "gradeOfRecommendation" : "",
                            "content": "Basistherapie mit {0}",
                            "preDefs": 
                            [
                                {
                                    "refId": 0,
                                    "type": "medication",
                                    "name" : "Pioglitazon",
                                    "comment" : "",
                                    "activeSubstance" : "Metformin",
                                    "dosageAmount" : "0",
                                    "dosageUnit" : "ml",
                                    "useSpecificDosageSchema": true,
                                    "morningDosage" : "0",
                                    "noonDosage" : "0",
                                    "eveningDosage" : "0",
                                    "nightDosage" : "0",
                                    "dosageFrequency" : "0",
                                    "dosageDuration" : "0",
                                    "dosageDurationUnit" : "days",
                                    "unlimitedApplicationDuration": true
                                }
                            ]
                        }
                    ]
                }
            ],
            "recommendations" : [
                {
                    "type": "syntax",
                    "title": "",
                    "primaryRecommendation": true,
                    "hideOnSublevelSelect": true,
                    "gradeOfEvidence" : "",
                    "gradeOfRecommendation" : "A",
                    "content": "Basistherapie mit {0}",
                    "preDefs": 
                    [
                        {
                            "refId": 0,
                            "type": "medication",
                            "name" : "Metformin",
                            "gradeOfEvidence" : "a",
                            "gradeOfRecommendation" : "2",
                            "comment" : "",
                            "activeSubstance" : "Metformin",
                            "dosageAmount" : "0",
                            "dosageUnit" : "ml",
                            "useSpecificDosageSchema": true,
                            "morningDosage" : "0",
                            "noonDosage" : "0",
                            "eveningDosage" : "0",
                            "nightDosage" : "0",
                            "dosageFrequency" : "0",
                            "dosageDuration" : "0",
                            "dosageDurationUnit" : "days",
                            "unlimitedApplicationDuration": true
                        }
                    ]
                }
            ],
            "levelName" : "Stufe 2: Therapierefraktärer Typ-2-Diabetes Mellitus auf Basistherapie über 3-6 Monate",
            "levelId" : "06781160-b732-11e8-8097-87b5bf74cf76",
            "definition": "Individueller HbA1c nach 3-6 Monaten nicht erreicht oder primär aussichtslos"
        },
        {
            "levels" : [
                
            ],
            "recommendations": [
                {
                    "type": "medication",
                    "name" : "Insulin",
                    "gradeOfEvidence" : "",
                    "gradeOfRecommendation" : "",
                    "comment" : "",
                    "activeSubstance" : "Metformin",
                    "dosageAmount" : "0",
                    "dosageUnit" : "ml",
                    "useSpecificDosageSchema": true,
                    "morningDosage" : "0",
                    "noonDosage" : "0",
                    "eveningDosage" : "0",
                    "nightDosage" : "0",
                    "dosageFrequency" : "0",
                    "dosageDuration" : "0",
                    "dosageDurationUnit" : "days",
                    "unlimitedApplicationDuration": true
                },
                {
                    "type": "group",
                    "title": "Empfohlen von DEGAM/AkdÄ",
                    "primaryRecommendation": true,
                    "hideOnSublevelSelect": true,
                    "comment": "Method. zuverlässige klin. Endpunktstudien, Nachteil Hypoglykämie, Gesichtszunahme",
                    "recommendations": 
                    [
                        {
                            "type": "medication",
                            "name" : "Metformin",
                            "gradeOfEvidence" : "",
                            "gradeOfRecommendation" : "",
                            "comment" : "",
                            "activeSubstance" : "Metformin",
                            "dosageAmount" : "20",
                            "dosageUnit" : "mg",
                            "useSpecificDosageSchema": true,
                            "morningDosage" : "1",
                            "noonDosage" : "0",
                            "eveningDosage" : "1.5",
                            "nightDosage" : "1",
                            "dosageFrequency" : "1",
                            "dosageDuration" : "10",
                            "dosageDurationUnit" : "days",
                            "unlimitedApplicationDuration": false
                        },
                        {
                            "type": "syntax",
                            "preDefs": [
                                {
                                    "type": "medication",
                                    "name" : "Insulin",
                                    "activeSubstance" : "",
                                    "dosageAmount" : "0",
                                    "dosageUnit" : "ml",
                                    "useSpecificDosageSchema": true,
                                    "morningDosage" : "0",
                                    "noonDosage" : "0",
                                    "eveningDosage" : "0",
                                    "nightDosage" : "0",
                                    "dosageFrequency" : "0",
                                    "dosageDuration" : "0",
                                    "dosageDurationUnit" : "days",
                                    "unlimitedApplicationDuration": true,
                                    "refId": 0
                                },
                                {
                                    "type": "medication",
                                    "name" : "Glibenclamid",
                                    "activeSubstance" : "",
                                    "dosageAmount" : "0",
                                    "dosageUnit" : "ml",
                                    "useSpecificDosageSchema": true,
                                    "morningDosage" : "0",
                                    "noonDosage" : "0",
                                    "eveningDosage" : "0",
                                    "nightDosage" : "0",
                                    "dosageFrequency" : "0",
                                    "dosageDuration" : "0",
                                    "dosageDurationUnit" : "days",
                                    "unlimitedApplicationDuration": true,
                                    "refId": 1
                                },
                                {
                                    "type": "medication",
                                    "name" : "DPP-4-Inhibitor",
                                    "activeSubstance" : "",
                                    "dosageAmount" : "200",
                                    "dosageUnit" : "ml",
                                    "useSpecificDosageSchema": true,
                                    "morningDosage" : "0",
                                    "noonDosage" : "0",
                                    "eveningDosage" : "0",
                                    "nightDosage" : "0",
                                    "dosageFrequency" : "0",
                                    "dosageDuration" : "0",
                                    "dosageDurationUnit" : "days",
                                    "unlimitedApplicationDuration": true,
                                    "refId": 2
                                }
                            ],
                            
                            "gradeOfEvidence" : "",
                            "gradeOfRecommendation" : "",
                            "comment" : "<b>Bei Insulin</b>: Methodisch zuverlässige klinische Endpunktstudien, Nachteil Hypoglykämie, Gewichtszunahme<br><br><b>Bei Glibenclamid</b>: Vorteil: Orale Gabe, Nachteil: höhere CVD Mortalität in methodisch nicht sehr guten Studien, Hypoglykämie, Gewichtszunahme<br><br><b>Bei DPP4-Inhibitor</b>: Vorteil: Orale Gabe, kaum Hypoglykämien, Gewichtsneutral, Nachteil: Keine Daten zu klinischen Endpunkten, Studien mit Hinweisen auf Zunahme von Pankreatitis, Pankreastumoren",
                            "content": "Entweder Insulin, {1|name} oder DPP-4-Inhibitor"
                        }
                    ]
                },
                {
                    "type": "group",
                    "title": "Empfohlen von DDG/DGIM: 2-fach Kombi aus",
                    "primaryRecommendation": true,
                    "hideOnSublevelSelect": true,
                    "comment": "",
                    "hideAnd": true,
                    "recommendations": 
                    [
                        {
                            "type": "medication",
                            "name" : "DPP-4-Inhibitor",
                            "gradeOfEvidence" : "",
                            "gradeOfRecommendation" : "",
                            "comment" : "",
                            "activeSubstance" : "",
                            "dosageAmount" : "0",
                            "dosageUnit" : "ml",
                            "useSpecificDosageSchema": true,
                            "morningDosage" : "0",
                            "noonDosage" : "0",
                            "eveningDosage" : "0",
                            "nightDosage" : "0",
                            "dosageFrequency" : "0",
                            "dosageDuration" : "0",
                            "dosageDurationUnit" : "days",
                            "unlimitedApplicationDuration": true
                        },
                        {
                            "type": "medication",
                            "name" : "GLP-1-Rezeptoragonist",
                            "gradeOfEvidence" : "",
                            "gradeOfRecommendation" : "",
                            "comment" : "",
                            "activeSubstance" : "",
                            "dosageAmount" : "0",
                            "dosageUnit" : "ml",
                            "useSpecificDosageSchema": true,
                            "morningDosage" : "0",
                            "noonDosage" : "0",
                            "eveningDosage" : "0",
                            "nightDosage" : "0",
                            "dosageFrequency" : "0",
                            "dosageDuration" : "0",
                            "dosageDurationUnit" : "days",
                            "unlimitedApplicationDuration": true
                        },
                        {
                            "type": "medication",
                            "name" : "Glukosidasehemmer",
                            "gradeOfEvidence" : "",
                            "gradeOfRecommendation" : "",
                            "comment" : "",
                            "activeSubstance" : "",
                            "dosageAmount" : "0",
                            "dosageUnit" : "ml",
                            "useSpecificDosageSchema": true,
                            "morningDosage" : "0",
                            "noonDosage" : "0",
                            "eveningDosage" : "0",
                            "nightDosage" : "0",
                            "dosageFrequency" : "0",
                            "dosageDuration" : "0",
                            "dosageDurationUnit" : "days",
                            "unlimitedApplicationDuration": true
                        },
                        {
                            "type": "medication",
                            "name" : "Insulin (häufig Verzögerungsinsulin)",
                            "gradeOfEvidence" : "",
                            "gradeOfRecommendation" : "",
                            "comment" : "",
                            "activeSubstance" : "",
                            "dosageAmount" : "0",
                            "dosageUnit" : "ml",
                            "useSpecificDosageSchema": true,
                            "morningDosage" : "0",
                            "noonDosage" : "0",
                            "eveningDosage" : "0",
                            "nightDosage" : "0",
                            "dosageFrequency" : "0",
                            "dosageDuration" : "0",
                            "dosageDurationUnit" : "days",
                            "unlimitedApplicationDuration": true
                        },
                        {
                            "type": "medication",
                            "name" : "SGLT2-Inhibtor",
                            "gradeOfEvidence" : "",
                            "gradeOfRecommendation" : "",
                            "comment" : "",
                            "activeSubstance" : "",
                            "dosageAmount" : "0",
                            "dosageUnit" : "ml",
                            "useSpecificDosageSchema": true,
                            "morningDosage" : "0",
                            "noonDosage" : "0",
                            "eveningDosage" : "0",
                            "nightDosage" : "0",
                            "dosageFrequency" : "0",
                            "dosageDuration" : "0",
                            "dosageDurationUnit" : "days",
                            "unlimitedApplicationDuration": true
                        },
                        {
                            "type": "medication",
                            "name" : "Sulfonylharnstoff / Glinid",
                            "gradeOfEvidence" : "",
                            "gradeOfRecommendation" : "",
                            "comment" : "",
                            "activeSubstance" : "",
                            "dosageAmount" : "0",
                            "dosageUnit" : "ml",
                            "useSpecificDosageSchema": true,
                            "morningDosage" : "0",
                            "noonDosage" : "0",
                            "eveningDosage" : "0",
                            "nightDosage" : "0",
                            "dosageFrequency" : "0",
                            "dosageDuration" : "0",
                            "dosageDurationUnit" : "days",
                            "unlimitedApplicationDuration": true
                        }
                    ]
                }
            ],
            "levelName" : "Stufe 3: Therapierefraktärer Typ-2-DM auf Basis + Pharmako-Monotherapie über 3-6 Monate",
            "levelId" : "06781160-b732-11e8-8097-87b5bf74cf76",
            "definition": "Individueller HbA1c nach 3-6 Monaten nicht erreicht"
        },
        {
            "recommendations": [
                {
                    "type": "freeText",
                    "title": "",
                    "content": "(Intensivierte) Insulintherapie (SIT, CT, ICT, CSII, Verzögerungsinsulin)",
                    "gradeOfEvidence": "",
                    "gradeOfRecommendation": "",
                    "primaryRecommendation": true,
                    "comment": "",
                    "hideOnSublevelSelect": true
                },
                {
                    "type": "group",
                    "title": "Empfohlen von DDG / DGIM",
                    "primaryRecommendation": true,
                    "hideOnSublevelSelect": false,
                    "comment": "",
                    "recommendations": 
                    [
                        {
                            "type": "freeText",
                            "title": "",
                            "content": "(Intensivierte) Insulintherapie (SIT, CT, ICT, CSII, Verzögerungsinsulin)",
                            "gradeOfEvidence": "",
                            "gradeOfRecommendation": "",
                            "primaryRecommendation": true,
                            "comment": ""
                        },
                        {
                            "type": "syntax",
                            "preDefs": 
                            [
                                {
                                    "refId": 0,
                                    "type": "medication",
                                    "name" : "Metformin",
                                    "gradeOfEvidence" : "",
                                    "gradeOfRecommendation" : "",
                                    "comment" : "",
                                    "activeSubstance" : "Metformin",
                                    "dosageAmount" : "0",
                                    "dosageUnit" : "ml",
                                    "useSpecificDosageSchema": true,
                                    "morningDosage" : "0",
                                    "noonDosage" : "0",
                                    "eveningDosage" : "0",
                                    "nightDosage" : "0",
                                    "dosageFrequency" : "0",
                                    "dosageDuration" : "0",
                                    "dosageDurationUnit" : "days",
                                    "unlimitedApplicationDuration": true
                                }
                            ],
                            "content" : "Orale Antidiabetika ({0}, Dpp-4-Inhibtor, SGLT-2-Inhibitor)",
                            "gradeOfEvidence" : "",
                            "gradeOfRecommendation" : "",
                            "comment" : ""
                        }
                    ]
                },
                {
                    "type": "group",
                    "title": "Empfohlen von DDG / DGIM",
                    "primaryRecommendation": true,
                    "hideOnSublevelSelect": false,
                    "comment": "",
                    "recommendations": 
                    [
                        {
                            "type": "freeText",
                            "title": "",
                            "content": "Verzögerungsinsulin",
                            "gradeOfEvidence": "",
                            "gradeOfRecommendation": "",
                            "primaryRecommendation": true,
                            "comment": ""
                        },
                        {
                            "type": "freeText",
                            "content" : "GLP-1-Rezeptorantagonist",
                            "gradeOfEvidence" : "",
                            "gradeOfRecommendation" : "",
                            "comment" : ""
                        }
                    ]
                }
            ],
            "levels" : [
                {
                    "levelName": "Adipös?",
                    "levelId": "lkjhsdflkbl1kjh412l34",
                    "recommendations": 
                    [
                        {
                            "type": "group",
                            "primaryRecommendation": true,
                            "hideOnSublevelSelect": false,
                            "comment": "",
                            "title": "Empfehlung bei Adipositas nach DEGAM / AkdÄ",
                            "recommendations": 
                            [
                                {
                                    "type": "freeText",
                                    "title": "",
                                    "content": "Insulin (SIT, CT, ICT)",
                                    "gradeOfEvidence": "",
                                    "gradeOfRecommendation": "",
                                    "primaryRecommendation": true,
                                    "comment": ""
                                },
                                {
                                    "type": "medication",
                                    "name" : "Metformin",
                                    "gradeOfEvidence" : "",
                                    "gradeOfRecommendation" : "",
                                    "comment" : "",
                                    "activeSubstance" : "Metformin",
                                    "dosageAmount" : "0",
                                    "dosageUnit" : "ml",
                                    "useSpecificDosageSchema": true,
                                    "morningDosage" : "0",
                                    "noonDosage" : "0",
                                    "eveningDosage" : "0",
                                    "nightDosage" : "0",
                                    "dosageFrequency" : "0",
                                    "dosageDuration" : "0",
                                    "dosageDurationUnit" : "days",
                                    "unlimitedApplicationDuration": true
                                }
                            ]
                        }
                    ]
                }
            ],
            "levelName" : "Stufe 4: Therapierefraktärer auf Insulin alleine / Pharmako 2-fach Kombi",
            "levelId" : "06781160-b732-11e8-8097-87b5bf74cf76",
            "definition": "Individueller HbA1c nach 3-6 Monaten nicht erreicht"
        }
    ]
 
}